Skip to content Skip to footer
Subscribe Now
Know Your Investor RA Capital Management (January’25 Edition)
INSIGHTS+

Know Your Investor: RA Capital Management (January’25 Edition)

Shots:   The January Edition features RA Capital Management, a global multi-stage investment firm dedicated to healthcare and life sciences In 2024, RA Capital added 74 companies to its portfolio, investing approximately $8.5B across seven funding rounds, including private and common funding Welcome to the 2025 series of Know Your Investor, a meticulously crafted report highlighting…
January 16, 2025

Read more

Know Your Investor- Samsara Biocapital (October’24 Edition)
INSIGHTS+

Know Your Investor: Samsara Biocapital (October’24 Edition)

Shots:  A California-based venture capital fund, Samsara Biocapital partners with medical companies and scientists to infuse cutting-edge innovations in medicines  In 2023, Samsara participated in five funding rounds and invested around $2.3B to add 19 companies to its portfolio  For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com …
October 17, 2024

Read more

Viewpoints_Efrat Kaduri
VIEWPOINTS

Off the Shelf Platform: Efrat Kaduri from Pluri Inc. In a Riveting Conversation with PharmaShots

Shots: Recently, Pluri launched its placental allogenic MAIT cell platform for immunotherapy treatment of solid tumors. Mucosal Associated Invariant T (MAIT) cells offer better advantages as compared to conventional T cells Today, we have with us Efrat Kaduri shedding light on the potential of placental MAIT cells in treating solid tumors While highlighting the intellectual…
July 10, 2024

Read more

Know Your Investor (June Edition): Google Ventures
INSIGHTS+

Know Your Investor (June Edition): Google Ventures

Shots:Google Ventures is an investment arm of Alphabet Inc. That invests profusely in seed-stage companies ranging from software and internet to healthcare, life sciences, and artificial intelligence among othersEver since 2016, GV pivoted to focusing on established companies. The company manages assets worth $10B and 400 active portfolio companies spanning across North America…
June 13, 2024

Read more

VIEWPOINTS_Angela Cacace_2024
VIEWPOINTS

Transformative Neurodegenerative Disorder Care: Angela Cacace in Conversation with PharmaShots

Shots:Angela Cacace Sr. VP, of Neuroscience and Platform Biology at Arvinas, shares insights from the preclinical trials evaluating ARV-102 for treatment of neurodegenerative diseases and dosing people with the first oral formulation (ARV-102) to treat neurodegenerative diseasesARV-102, a novel oral PROTAC® protein degrader, is designed to cross the blood-brain barrier and target leucine-rich repeat kinase…
April 29, 2024

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]